Nadroparin: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
No edit summary |
||
| Line 25: | Line 25: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
==Overview== | ==Overview== | ||
'''Nadroparin''' is a form of [[low molecular weight heparin]]. | '''Nadroparin''' is a form of [[low molecular weight heparin]]. | ||
==External Links== | |||
==External | |||
* http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128 | * http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128 | ||
* http://www.mayoclinic.com/health/drug-information/DR600971 | * http://www.mayoclinic.com/health/drug-information/DR600971 | ||
* {{cite journal |author=Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A |title=A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study |journal=Pharmacology |volume=78 |issue=3 |pages=136-43 |year=2006 |pmid=17057417 |doi=10.1159/000096484}} | * {{cite journal |author=Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A |title=A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study |journal=Pharmacology |volume=78 |issue=3 |pages=136-43 |year=2006 |pmid=17057417 |doi=10.1159/000096484}} | ||
==References== | |||
{{reflist|2}} | |||
{{Antithrombotics}} | {{Antithrombotics}} | ||
[[Category:Drug]] | |||
[[Category:Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Anticoagulants]] | |||
Latest revision as of 00:48, 26 July 2014
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Molar mass | Mean MW = 4500 Daltons |
|
WikiDoc Resources for Nadroparin |
|
Articles |
|---|
|
Most recent articles on Nadroparin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Nadroparin at Clinical Trials.gov Clinical Trials on Nadroparin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Nadroparin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Nadroparin Discussion groups on Nadroparin Patient Handouts on Nadroparin Directions to Hospitals Treating Nadroparin Risk calculators and risk factors for Nadroparin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Nadroparin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Nadroparin is a form of low molecular weight heparin.
External Links
- http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
- http://www.mayoclinic.com/health/drug-information/DR600971
- Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology. 78 (3): 136–43. doi:10.1159/000096484. PMID 17057417.
References
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- CS1 maint: Multiple names: authors list
- Drug
- Cardiovascular Drugs
- Anticoagulants